Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for CRISPR Therapeutics in a note issued to investors ...

Discover the Vanguard Mega Cap Value ETF (MGV) - a value-focused investment option offering low volatility and attractive ...

Check the time stamp on this data. Updated AI-Generated Signals for Crispr Therapeutics Ag (CRSP) available here: CRSP. Type ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other biotech ...

CRISPR Therapeutics AG (CRSP) shares rallied 6.5% in the last trading session to close at $44.20. This move can be attributable to notable volume with a higher number of shares being traded than ...

Stock analysts at Cantor Fitzgerald issued their FY2025 earnings per share (EPS) estimates for shares of CRISPR Therapeutics ...

Crispr Therapeutics AG (CRSP) stock saw a decline, ending the day at $38.85 which represents a decrease of $-0.84 or -2.12% from the prior close of $39.69. The stock opened at $39.06 and touched a low ...

CRISPR stock decline is influenced by Editas Medicine's struggles, but CRSP remains strong with FDA approval and strategic ...

ZUG, Switzerland and BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...